Directory
Headshot of Christopher Coss

Christopher Coss, PhD

Associate Professor

Pharmaceutics and Pharmacology
Research Areas: The Division of Pharmaceutics & Pharmacology, Cancer

504 Riffe

coss.16@osu.edu
(614) 688-1309
 Professional Website

Professional Interests

Dr. Coss' research focuses on endocrine disease mechanisms and developing novel therapies for advanced prostate cancer. He also has an interest in chemoprevention of prostate and hepatocellular carcinomas using novel hormonal approaches.

Education

  • 2008, PhD, The Ohio State University, Pharmacy, Pharmaceutical Sciences, and Administration, Other
  • 2003, BS, Cum Laude with Honors, The Ohio State University, Molecular Genetics
  • 2003, BS, Cum Laude with Honors, The Ohio State University, Computer Science

Honors

  • Endocrine Society Early Investigator Award, 2015 - 2016

Publications

  • Sedlák D, Wilson TA, Tjarks W, Radomska HS, Wang H, Kolla JN, Leśnikowski ZJ, Špičáková A, Ali T, Ishita K, Rakotondraibe LH, Vibhute S, Wang D, Anzenbacher P, Bennett C, Bartunek P, Coss CC. Structure-Activity Relationship of Carborane Selective Estrogen Receptor β Agonists. J Med Chem. 2021 Jul 8;64(13):9330-9353. doi: 10.1021/acs.jmedchem.1c00555. Epub 2021 Jun 28. PMID: 34181409.
  • Collier KA, Valencia H, Newton H, Hade EM, Sborov DW, Cavaliere R, Poi M, Phelps MA, Liva SG, Coss CC, Wang J, Khountham S, Monk P, Shapiro CL, Piekarz R, Hofmeister CC, Welling DB, Mortazavi A. A phase 1 trial of the histone deacetylase inhibitor AR-42 in patients with neurofibromatosis type 2-associated tumors and advanced solid malignancies. Cancer Chemother Pharmacol. 2021 May;87(5):599-611. doi: 10.1007/s00280-020-04229-3. Epub 2021 Jan 25. PMID: 33492438; PMCID: PMC8162746.
  • Zhang P, Brinton LT, Williams K, Sher S, Orwick S, Tzung-Huei L, Mims AS, Coss CC, Kulp SK, Youssef Y, Chan WK, Mitchell S, Mustonen A, Cannon M, Phillips H, Lehman AM, Kauffman T, Beaver L, Canfield D, Grieselhuber NR, Alinari L, Sampath D, Yan P, Byrd JC, Blachly JS, Lapalombella R. Targeting DNA Damage Repair Functions of Two Histone Deacetylases, HDAC8 and SIRT6, Sensitizes Acute Myeloid Leukemia to NAMPT Inhibition. Clin Cancer Res. 2021 Apr 15;27(8):2352-2366. doi: 10.1158/1078-0432.CCR-20-3724. Epub 2021 Feb 4. PMID: 33542077; PMCID: PMC8054771.
  • Helms TH, Mullins RD, Thomas-Ahner JM, Kulp SK, Campbell MJ, Lucas F, Schmidt N, LeMoine DM, Getaneh S, Xie Z, Phelps MA, Clinton SK, Coss CC. Inhibition of androgen/AR signaling inhibits diethylnitrosamine (DEN) induced tumour initiation and remodels liver immune cell networks. Sci Rep. 2021 Feb 11;11(1):3646. doi: 10.1038/s41598-021-82252-x. PMID: 33574348; PMCID: PMC7878907.
  • Mukherjee D, DiVincenzo MJ, Torok M, Choueiry F, Kumar RJ, Deems A, Miller JL, Hinton A, Geraghty C, Maranon JA, Kulp SK, Coss C, Carson WE 3rd, Conwell DL, Hart PA, Cooperstone JL, Mace TA. Soy-tomato enriched diet reduces inflammation and disease severity in a pre-clinical model of chronic pancreatitis. Sci Rep. 2020 Dec 11;10(1):21824. doi: 10.1038/s41598-020-78762-9. PMID: 33311549; PMCID: PMC7733503.
  • Xie Z, Chen M, Goswami S, Mani R, Wang D, Kulp SK, Coss CC, Schaaf LJ, Cui F, Byrd JC, Jennings RN, Schober KK, Freed C, Lewis S, Malbrue R, Muthusamy N, Bennett C, Kisseberth WC, Phelps MA. Pharmacokinetics and Tolerability of the Novel Non-immunosuppressive Fingolimod Derivative, OSU-2S, in Dogs and Comparisons with Data in Mice and Rats. AAPS J. 2020 Jul 16;22(4):92. doi: 10.1208/s12248-020-00474-9. PMID: 32676788; PMCID: PMC7814188.
  • Liva SG, Coss CC, Wang J, Blum W, Klisovic R, Bhatnagar B, Walsh K, Geyer S, Zhao Q, Garzon R, Marcucci G, Phelps MA, Walker AR. Phase I study of AR-42 and decitabine in acute myeloid leukemia. Leuk Lymphoma. 2020 Jun;61(6):1484-1492. doi: 10.1080/10428194.2020.1719095. Epub 2020 Feb 8. PMID: 32037935; PMCID: PMC7375689.
  • Jain R, Coss C, Whooley P, Phelps M, Owen DH. The Role of Malnutrition and Muscle Wasting in Advanced Lung Cancer. Curr Oncol Rep. 2020 May 15;22(6):54. doi: 10.1007/s11912-020-00916-9. PMID: 32409907.
  • Liva SG, Tseng YC, Dauki AM, Sovic MG, Vu T, Henderson SE, Kuo YC, Benedict JA, Zhang X, Remaily BC, Kulp SK, Campbell M, Bekaii-Saab T, Phelps MA, Chen CS, Coss CC. Overcoming resistance to anabolic SARM therapy in experimental cancer cachexia with an HDAC inhibitor. EMBO Mol Med. 2020 Feb 7;12(2):e9910. doi: 10.15252/emmm.201809910. Epub 2020 Jan 13. PMID: 31930715; PMCID: PMC7005646.
  • Dauki AM, Blachly JS, Kautto EA, Ezzat S, Abdel-Rahman MH, Coss CC. Transcriptionally Active Androgen Receptor Splice Variants Promote Hepatocellular Carcinoma Progression. Cancer Res. 2020 Feb 1;80(3):561-575. doi: 10.1158/0008-5472.CAN-19-1117. Epub 2019 Nov 4. PMID: 31685543; PMCID: PMC7002251.